1)日本医学会:医療における遺伝学的検査・診断に関するガイドライン.2011年2月 https://jams.med.or.jp/guideline/genetics-diagnosis.html
2)Collaborative Group on Hormonal Factors in Breast Cancer : Familial breast cancer : collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358 : 1389-1399, 2001
3)Miki Y, et al : A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 : 66-71, 1994
4)Kuchenbaecker KB, et al : Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317 : 2402-2416, 2017
5)Knudson AG Jr : Mutation and cancer : statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68 : 820-823, 1971
6)Norquist BM, et al : Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2 : 482-490, 2016
7)Enomoto T, et al : The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer : CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA(CHARLOTTE). Int J Gynecol Cancer 29 : 1043-1049, 2019
8)日本婦人科腫瘍学会 : 卵巣癌患者に対してコンパニオン診断としてBRCA1あるいはBRCA2の遺伝学的検査を実施する際の考え方.2021年3月26日改訂 https://jsgo.or.jp/opinion/02.html
9)Ray-Coquard I, et al : Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381 : 2416-2428, 2019
10)Moore KN, et al : Niraparib monotherapy for late-line treatment of ovarian cancer(QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20 : 636-648, 2019